Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.

Antoine Reveau

Gilles Avenard

Acticor Biotech SAS

Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.

Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. 
Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. 

However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.

This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France.
The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).

Mediolanum Farmaceutici S.p.A.

Mirae Capital

Newton Biocapital

CMS Medical Venture Investment

Karista

Mirae Asset

GO CAPITAL

A&B (HK)

Anaxago

Acticor Biotech

[#GlenzoPaper]

🌟 Exciting News! ACTIMIS Clinical Study Results have been officially published in The Lancet Neurology Journal 🧠🌐 

📰 Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a phase 1b/2a randomized, placebo-controlled, trial 

🔎 This article highlights key outcomes from the ACTIMIS study : 

✅ Achievement of ACTIMIS primary endpoint, confirming the safety of glenzocimab in acute ischemic stroke patients

📉 Reduction in the rate and severity of intracranial hemorrhages and of mortality in glenzocimab-treated patients

🔗Access the full paper on The Lancet website : https://lnkd.in/etYUfpMq

#ACTIMIS #MedicalResearch #StrokeTreatment #HealthcareInnovation

[#GlenzoPaper]

🎙️ Gilles Avenard, CEO d'Acticor Biotech, revient sur la parution des résultats d'ACTIMIS dans The Lancet lors d'un entretien avec Nathalie Brafman dans Le Monde 🌍 

🔗 Lien vers l'article : https://lnkd.in/e-Pu4jnu

#interview #ACTIMIS #LeMonde

[#GlenzoPaper]

"AVC - l'anticorps d'une biotech française qui pourrait réduire de moitié le risque de décès" 🚑 

✍ Publié dans Le Figaro, cet article revient sur la publication des résultats de l'étude ACTIMIS dans The Lancet Neurogoly avec le témoignage du Pr. Charlotte Cordonnier - chef du service de neurologie vasculaire au CHU de Lille et celui du Pr. Mikael Mazighi - chef du service de neurologie à l'hôpital Lariboisère 🗣 📰

Lien de l'article : https://lnkd.in/ewMunHan 🌐 

#ACTIMIS #interview #glenzocimab

[#GlenzoPaper]

Aujourd'hui, le Pr. Mikael Mazighi, chef de la neurologie à l'hôpital Lariboisière et coordinateur principal de l'étude ACTIMIS, était invité dans le Journal de 8h animé par Florence Paracuellos sur France Inter 🎙️

Il a partagé plus en détail les résultats de l'étude récemment publiés dans The Lancet ! 📊

Si vous avez manqué l'interview, vous pouvez trouver le podcast du journal ici (01:29 - 03:10) :  https://lnkd.in/eWVhdYwJ
Et pour plus d'infos, jetez un œil à l'article : https://lnkd.in/e9m5zqMs 📰

#ACTIMIS #interview #glenzocimab 

Metric
Company Name	Acticor Biotech SAS
Symbol	ALACT
MSH ID	COM:ACTICOR-BIOTECH
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	FR
Stage
Employee Count	29
Website	acticor-biotech.com
LinkedIn	acticor-biotech
Founders

Metric
Market Cap	9.16M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ACTICOR-BIOTECH

Acticor Biotech

Last Close

0.30

25/11 08:00

Market Cap

8.67M

Beta: -

Volume Today

50

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue